Newbury Pharmaceuticals AB (publ) reported earnings results for the fourth quarter and full year ended August 31, 2023. For the fourth quarter, the company reported sales was SEK 2.83 million compared to SEK 4.57 million a year ago. Net loss was SEK 4.75 million compared to SEK 3.9 million a year ago.
For the full year, sales was SEK 10.27 million compared to SEK 5.52 million a year ago. Net loss was SEK 19.43 million compared to SEK 14.67 million a year ago.